论文部分内容阅读
作者对27例转移性黑色素瘤患者注射rIL-2加LAK细胞输注并交替应用连续氮烯咪胺化疗。在前5天,连续注射rIL-2,间歇1天,进行4天白细胞提取以使体外LAK细胞扩增,随后4 1/2天连续注射rIL-2,并在其前3天协同回输LAK细胞。2周后,病人接受氮烯咪胺化疗(1200mg/m~2)。结果,2例完全缓解,5例部分缓解,有效率26％(12％～47％)。3例呈混合反应。部分缓解与混合反应是短暂的,时间从1个月至6个月不等。2例完全缓解者分别维持13~+和14~+个月。除2例因血小板减少而延误治疗外,此方案没有其他附加毒性反应。病人交替应用输注免
The authors infused 27 patients with metastatic melanoma with rIL-2 plus LAK cells and alternated continuous nedatimide chemotherapy. In the first 5 days, rIL-2 was continuously injected, intermittently for 1 day, 4 days of leukocyte extraction was performed to expand LAK cells in vitro, followed by continuous injection of rIL-2 for 4 1/2 days, and synergistic reinfusion of LAK in the first 3 days. cell. Two weeks later, the patient received noltamine chemotherapy (1200 mg/m~2). As a result, 2 patients achieved complete remission and 5 patients achieved partial remission with an effective rate of 26% (12% to 47%). 3 cases showed a mixed reaction. Partial remissions and mixed reactions are transient and vary from 1 month to 6 months. Two cases of complete remission were maintained for 13~+ and 14~+ months, respectively. Except for 2 cases of delayed treatment due to thrombocytopenia, there were no other additional toxicities in this regimen. Patients alternately apply transfusions